Market Size Expending in Generic Pharmaceutical Industry

Last week, statistics report released leading global health research company _EvaluatePharm said in 2014 to 2020 of 7 years, there will be $259bn drugs facing the risks of patent expirations, which is expected to 46% of the market share will be generics erodes.

Found by searching, 2016 to 2027 patent expired drugs for tumor, in addition to have been listed, the domestic enterprises are waiting for approval with the amine, abiraterone, erlotinib imatinib, sunitinib Nepal, sorafenib, lapatinib nylon 6 varieties. Among them, Cologne Pharmaceutical (002422) to declare the 3 varieties among them.

Analysts said that today, with a large number of foreign patent medicine expires, the domestic policy tends to loose, in imitation of the Chinese pharmaceutical industry is being ushered in an unprecedented opportunity, by 2015, the size of the market may close to 500 billion yuan. The personage inside course of study points out, at present, the slow growth of the world drug market is only an average of 4-5%, but generic pharmaceutical and biotechnology industry has come to the fore, are at an average of 11% and 10% of the increase in become leading the global industry sustainable development dynamic sector, but also inspire a new market - biosimilars industry.

At present, our country has been able to produce some biosimilars, has approved the listing of the 13 categories of 25 only 382 different specifications of the genetic engineering drugs and gene engineering vaccine products, 6 9 21 specifications products belong to the original, and the rest belong to the imitation.